Document Type : Original Article


1 Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran

2 Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Interventional Cardiology Research Center, Cardiovascular Research Institute. Isfahan University of Medical Sciences, Isfahan, Iran

4 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran



INTRODUCTION: Coronary heart disease (CHD) contributes significantly to mortality and morbidity in Iran. A model was fitted in this study to determine changes in risk factors and treatment uptake to CHD mortality rate reduction in Isfahan between 2007 and 2016.
METHOD: The IMPACT model was fitted to determine how much the decrease in CHD death can be explained by treatment uptake and significant risk factors included in the analyses for adults aged 35 to 84 years. Body mass index (BMI), diabetes, and smoking were considered as the CHD risk factors in the model. Medical and interventional treatments were studied in four different groups of patients. The primary data sources were obtained from the Persian registry of cardiovascular disease (PROVE), The Isfahan healthy heart program (IHHP), and the impact of self-care management and adopted Iranian guidelines for hypertension treatment on improving the control rate of hypertension (IMPROVE CARE) study, death registration system, and the Isfahan province Cemetery.
RESULTS: The CHD mortality rate decreased by 14% between 2007 and 2016 in Iran for adults aged 35 to 84 years and prevented or delayed 212 CHD deaths in 2016. Treatment uptakes caused 99% postponed or prevented death. Treatment for heart failure in hospitals explained approximately half of the death prevented by treatment. Risk factors caused about 15% of excess death. It appears that the prevalence of CHD is increasing while the death rate is decreasing because of these observed changes.
CONCLUSION: Risk factors worsened in 2016 and, without treatment, could lead to an increase in CHD mortality in Iran. Preventive policies should control the risk factor and contribute to the decrease in CHD death.


1. Keil U. The Worldwide WHO MONICA Project: results and perspectives. Gesundheitswesen 2005; 67 Suppl 1: S38-45.
2. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984; 76(2a): 4-12.
3. Shams-Beyranvand M, Farzadfar F, Naderimagham S, Tirani M, Maracy MR. Estimation of burden of ischemic heart diseases in Isfahan, Iran, 2014: using incompleteness and misclassification adjustment models. J Diabetes Metab Disord 2017; 16: 12.
4. Ferdosi M, Mohammadi Sefiddashti F, Aghdak P, Moradi R, Mofid M, Rejalian F, et al. Death ‎Portrait of Isfahan Province in Years 2007-2011. Int J Prev Med 2016; 7: 96.
5. Kohi F, Salehinia H, Mohammadian-Hafshejani A. Trends in mortality from cardiovascular disease ‎in Iran from 2006-2010. J Sabzevar Univ Med Sci 2015; 22(4): 630-8. 
6. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, et al. Analysing ‎the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One 2010; 5(11): e13957.
7. Unal B, Sözmen K, Arık H, Gerçeklioğlu G, Altun DU, Şimşek H, et al. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. BMC Public Health 2013; 13: 1135.
8. Koopman C, Vaartjes I, van Dis I, Verschuren WM, Engelfriet P, Heintjes EM, et al. Explaining the Decline in Coronary Heart Disease Mortality in the Netherlands between 1997 and 2007. PLoS One 2016; 11(12): e0166139.
9. Raghfar H, Sargazi N, Mehraban S, Akbarzadeh MA, Vaez Mahdavi MR, Vahdati Manesh Z. The Economic Burden of Coronary Heart Disease in Iran: A Bottom-up Approach in 2014. J Ardabil Univ Med Sci 2018; 18(3): 341-56.
10. Unal B, Critchley JA, Capewell S. Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000. Circulation 2004; 109(9): 1101-7.
11. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the Increase in Coronary Heart Disease Mortality in Beijing Between 1984 and 1999. Circulation 2004; 110(10): 1236-44.
12. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81(4): 380-6.
13. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the Decline in Coronary Heart Disease Mortality Rates in Auckland, New Zealand, Between 1982 and 1993. Circulation 2000; 102(13): 1511-6.
14. Explaining the decline in coronary heart disease mortality rates in Japan: Contributions of changes ‎in risk factors and evidence-based treatments between 1980 and 2012. Int J Cardiol 2019; 291: 183-8.
15. Decrease in U.S. Deaths from Coronary Disease. N Engl J Med 2007; 357(9): 941.
16. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the Decline in Coronary Heart Disease Mortality in Finland between 1982 and 1997. Am J Epidemiol 2005; 162(8): 764-73.
17. Nouri F, Feizi A, Taheri M, Mohammadifard N, Khodarahmi S, Sadeghi M, et al. Temporal Trends of the Incidence of Ischemic Heart Disease in Iran Over 15 Years: A Comprehensive Report from a Multi-Centric Hospital-Based Registry. Clin Epidemiol 2020; 12: 847-56.
18. Sheidaei A, Gohari K, Kasaeian A, Rezaei N, Mansouri A, Khosravi A, et al. National and Subnational Patterns of Cause of Death in Iran 1990-2015: Applied Methods. Arch Iran Med 2017; 20(1): 2-11. 
19. Eghbali-Babadi M, Khosravi A, Feizi A, Sarrafzadegan N. Design and implementation of a combined observational and interventional study: Trends of prevalence, awareness, treatment and control hypertension and the effect of expanded chronic care model on control, treatment and self-care. ARYA Atheroscler 2017; 13(5): 211-20. 
20. Eghbali M, Khosravi A, Feizi A, Mansouri A, Mahaki B, Sarrafzadegan N. Prevalence, awareness, treatment, control, and risk factors of hypertension among adults: a cross-sectional study in Iran. Epidemiol Health 2018; 40: e2018020-e.
21. Givi M, Heshmat-Ghahdarijani K, Garakyaraghi M, Yadegarfar G, Vakhshoori M, Heidarpour M, et ‎al. Design and methodology of heart failure registry: Results of the Persian registry of cardiovascular ‎disease. ARYA Atheroscler 2019; 15(5): 228-32.
22. Givi M, Sarrafzadegan N, Garakyaraghi M, Yadegarfar G, Sadeghi M, Khosravi A, et al. Persian Registry Of cardioVascular diseasE (PROVE): Design and methodology. ARYA Atheroscler 2017; 13(5): 236-44.
23. Khosravi A, Mansouri A, Shahsanayi F, Paydari N, Heshmat-Ghahdarijani K, Mansourian M, et al. Rationale and Design of the Persian CardioVascular Disease Registry (PCVDR): Scale-Up of Persian Registry ‎‎Of CardioVascular DiseasE (PROVE). Curr Probl Cardiol 2021; 46(3): 100577.
24. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S, et al. Isfahan Healthy Heart Programme: a comprehensive integrated community-based programme for cardiovascular ‎disease prevention and control. Design, methods and initial experience. Acta Cardiol 2003; 58(4): 309-20.
25. Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366(9489): 914-20.‎
26. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of Temporal Trends in Risk Factors and Treatment Uptake With Coronary Heart Disease Mortality, 1994-2005. JAMA 2010; 303(18): 1841-7.
27. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318(7200): 1730-7.
28. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, ‎‎myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
29. Ezzati M, Lopez AD, Rodgers AA, Murray CJL. Comparative quantification of health risks : global and regional burden of disease attributable to selected major risk factors / edited by Majid Ezzati … [et al.]. Geneva: World Health Organization; 2004.
30. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344(8922): 563-70.
31. Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166(17): 1814-21.
32. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in ‎‎patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215): 1575-81.
33. Roglic G, Unwin N. Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 2010; 87(1): 15-9.
34. Bogers RP, Hoogenveen R, Boshuizen H, Woodward M, Knekt P, van Dam R, et al. Overweight and ‎‎obesity increase the risk of coronary heart disease: A pooled analysis of 30 prospective studies. 2011.
35. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for ‎acute ‎myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361(9351): 13-20.
36. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the ‎Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-9.
37. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular ‎‎mortality. Circulation 2005; 112(4): 489-97.
38. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality ‎and hospital admissions in heart failure. Eur J Heart Fail 2001; 3(3): 351-7.
39. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases ‎of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2(8607): 349-60.
40. Nichol MB, Venturini F, Sung JCY. A Critical Evaluation of the Methodology of the Literature on ‎‎Medication Compliance. Ann Pharmacother 1999; 33(5): 531-40.
41. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. BMJ 1995; 311(7008): 793-6.
42. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of ‎‎contribution of changes in classic risk factors to trends in coronary-event rate across the WHO MONICA ‎Project populations. Lancet 2000; 355: 675-87.
43. Critchley JA, Capewell S. Why model coronary heart disease? Eur Heart J 2002; 23(2): 110-6.
44. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3(2): 95-104.
45. Ahmadi A, Mobasheri M, Soori H. Prevalence of major coronary heart disease risk factors in Iran. Int J Epidemiol Res 2014; 1(1): 3-8.
46. Abu-Rmeileh NM, Shoaibi A, O’Flaherty M, Capewell S, Husseini A. Analysing falls in coronary heart ‎‎disease mortality in the West Bank between 1998 and 2009. BMJ Open 2012; 2(4).
47. Ogata S, Nishimura K, Guzman-Castillo M, Sumita Y, Nakai M, Nakao YM, et al. Explaining the decline in ‎coronary heart disease mortality rates in Japan: Contributions of changes in risk factors and evidence-based treatments between 1980 and 2012. Int J Cardiol 2019; 291: 183-8.
48. Unal B, Critchley JA, Fidan D, Capewell S. Life-years gained from modern cardiological treatments ‎and population risk factor changes in England and Wales, 1981-2000. Am J Public Health 2005; 95(1): 103-8.
49. Cooper K, Davies R, Roderick P, Chase D, Raftery J. The development of a simulation model of the treatment of coronary heart disease. Health Care Manag Sci 2002; 5(4): 259-67.
50. Horikawa C, Sone H. Dietary salt intake and diabetes complications in patients with diabetes: An ‎overview. J Gen Fam Med 2017; 18(1): 16-20.
51. Mohammadifard N, Khosravi A, Salas-Salvadó J, Becerra-Tomás N, Nouri F, Abdollahi Z, et al. Trend of salt intake measured by 24-hour urine collection samples among Iranian adults population between 1998 ‎and 2013: The Isfahan salt study. Nutr Metab Cardiovasc Dis 2019; 29(12): 1323-9.
52. Alimohammadi M, Jafari-Mansoorian H, Hashemi SY, Momenabadi V, Ghasemi SM, Karimyan K. Review ‎on the Implementation of the Islamic Republic of Iran about Tobacco Control, Based on MPOWER, ‎in the Framework Convention on Tobacco Control by the World Health Organization. Addict Health 2017; 9(3): 183-9.
53. Guzman-Castillo M, Ahmed R, Hawkins N, Scholes S, Wilkinson E, Lucy J, et al. The contribution of ‎‎primary prevention medication and dietary change in coronary mortality reduction in England between 2000 and 2007: a modelling study. BMJ Open 2015; 5(1): e006070-e.
54. Sutherland J, Edwards P, Shankar B, Dangour AD. Fewer adults add salt at the table after initiation ‎of a national salt campaign in the UK: a repeated cross-sectional analysis. Br J Nutr 2013; 110(3): 552-8.
55. VanWormer JJ, Boucher JL. Motivational interviewing and diet modification: a review of the ‎evidence. Diabetes Educ 2004; 30(3): 404-6, 8-10, 14-6 passim.
56. Goyer L, Dufour R, Janelle C, Blais C, L’Abbé C, Raymond E, et al. Randomized controlled trial on ‎the long-term efficacy of a multifaceted, interdisciplinary lifestyle intervention in reducing cardiovascular risk and improving lifestyle in patients at risk of cardiovascular disease. J Behav Med 2013; 36(2): 212-24.
57. Populations WHOFoRSIi, World Health O, Populations WHOTMoRSIi. Reducing salt intake in populations : report of a WHO forum and technical meeting, 5-7 October 2006, Paris, France. Geneva: World Health Organization; 2007.
58. Unal B, Critchley J, Capewell S. Missing, mediocre, or merely obsolete? An evaluation of UK data ‎‎sources for coronary heart disease. J Epidemiol Community Health 2003; 57: 530-5.
59. McGovern PG, Jacobs DR, Jr., Shahar E, Arnett DK, Folsom AR, Blackburn H, et al. Trends in acute ‎‎coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota ‎‎heart survey. Circulation 2001; 104(1): 19-24.‎
60. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83(4): 1194-201.